Innova Captab has accorded in-principle approval for the acquisition of land with an estimated investment of approximately ₹50 crore. The Board of Directors sanctioned the move during its meeting held on September 3, 2026.

The company stated that it will provide further updates once the final purchase and sale agreement is executed between the parties. This disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the Master Circular dated January 30, 2026.

The board meeting commenced at 8:01 am and concluded at 8:19 am. Neeharika Shukla, Company Secretary and Compliance Officer, signed the communication addressed to BSE and NSE.

Innova Captab revised its consolidated financial results for the quarter and fiscal year ended March 31, 2026, following the identification of inadvertent accounting errors. The Board of Directors approved the restated figures on August 21, 2026, alongside a plan to expand its manufacturing capacity in Himachal Pradesh.

The revisions primarily involved the retrospective correction of deferred tax liabilities related to a historical business combination and the recognition of a deferred tax asset under Section 80JJAA of the Income Tax Act. Additionally, the company reclassified ₹185.08 million in supplier finance arrangements from trade payables to other financial liabilities.

Revised Financial Performance

For the quarter ended March 31, 2026, consolidated revenue from operations stood at ₹4,478.02 million, up from ₹3,147.41 million in the corresponding quarter of the previous year. Consolidated net profit for the period rose to ₹403.49 million, compared to ₹285.66 million in Q4FY25.

For the full fiscal year ended March 31, 2026, consolidated revenue reached ₹16,300.18 million, an increase from ₹12,436.76 million in FY25. Net profit for the year was reported at ₹1,431.83 million, up from ₹1,272.51 million in the prior year.

What the Numbers Show

The revision of the deferred tax liability related to the acquisition of Sharon Bio-Medicine Limited had a material impact on equity. As of April 1, 2024, total assets were reduced by ₹105.37 million due to this correction. Similarly, for the year ended March 31, 2025, deferred tax expense increased by ₹10.07 million, reducing the previously reported profit for the year by the same amount. The recognition of the Section 80JJAA tax asset in FY26 reduced the total tax expense by ₹22.66 million compared to the originally approved figures, thereby boosting the reported net profit.

Capacity Expansion Plan

The Board approved a brownfield expansion of the manufacturing facility located at Baddi, Himachal Pradesh. The project involves adding two Oral Solid Dosage production lines to the existing infrastructure, which currently operates at approximately 85% to 90% capacity utilization.

• Investment: Approximately ₹45 crore
• Financing: Bank credit facilities and internal accruals
• Timeline: Expected completion within 18 to 22 months

The expansion aims to improve operational efficiency and support long-term growth strategies. Statutory auditors B S R & Co. LLP issued an unmodified opinion on the revised standalone and consolidated financial results.